Usefulness of three-drug additional combination therapy with bucillamine, sulfasalazine and methotrexate for refractory rheumatoid arthritis

International Journal of Immunotherapy

Volumn 18, Issue 2, 2002, Pages 57-64

  Hamada, Y ^a   Shinomiya, F ^a   Okada, M ^a   Fujimura, T ^a  

^a Tokushima Kensei Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; AURANOFIN; AUROTHIOMALATE; BUCILLAMINE; C REACTIVE PROTEIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; PENICILLAMINE; SALAZOSULFAPYRIDINE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BLOOD TOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DETERIORATION; DISEASE ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INFLAMMATION; LIVER DISEASE; LOW DRUG DOSE; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEPHROTOXICITY; PRURITUS; RASH; RHEUMATOID ARTHRITIS; STOMATITIS; TREATMENT OUTCOME;

EID: 0038655594     PISSN: 02559625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Rosenthal M. Loss of efficacy of anti-rheumatic drugs in rheumatoid arthritis. J. Rheumatol., 7, 586, 1980.
2. Shinomiya F. et al. Outcome of step-wise use of DMARDs in patients with early rheumatoid arthritis. The second report: Changes in X-ray findings over 5 years Rheumatology, 16, 405, 1996.
3. Shinomiya F. et al. Outcome of step-wise use of DMARDs in patients with early rheumatology arthritis. Clinical efficacy of DMARDs therapy in delaying the progress of multiple joint destruction. Igaku no Ayumi, 186, 149, 1998.
4. Takasugi K. Evaluation of bucillamine in the treatment of active rheumatoid arthritis. Clin. Rheumatol., 1, 144, 1988.
5. Singler J.W. et al. Gold salts in the treatment of rheumatoid arthritis: A double-blind study. Ann. Intern. Med., 80, 21, 1974.
6. Shinomiya F. et al. Efficacy of auranofin administration for patients with early rheumatoid arthritis. Medical Consultation & New Remedies, 29, 1419, 1992.
7. Bird H.A., Dixon J.S., Pickup M.E. et al. A biochemical assessment of sulfasalazine in rheumatoid arthritis. J. Rheumatol., 9, 36, 1982.
8. Hamada Y. et al. Clinical application of sulfasalazine to the treatment of rheumatoid arthritis. Rheumatology, 18, 493, 1977.
9. Takasugi K. Loss of drug efficacy in rheumatoid arthritis. Rheumatology, 14, 283, 1995.
10. Ichikawa Y. et al. Salazosulfapyridine in the long-term treatment of rheumatoid arthritis. Ryumachi, 35, 663, 1995.
11. Abe C. et al. Combination therapy on murine arthritis: Salazosulfapyridine, bucillamine and methotrexate. Int. J. Immunotherapy, 11, 129, 1995.
12. Nisar M., Carlisle L., Amos R.S. et al. Methotrexate and sulphasalazine as combination therapy in rheumatoid arthritis. Br. J. Rheumatol., 33, 651, 1994.
13. Wilske K.R. Remodeling the pyramid: A concept whose time has come. J. Rheumatol., 19, 565, 1989.
14. Nobunaga M. Combination therapy with disease-modifying anti-rheumatic drugs. Ryumachi, 34, 88, 1994.
15. Sievers K. et al. Combined therapy of rheumatoid arthritis with gold and chloroquine. Act. Rheumatol. Scand., 9, 48, 1963.
16. Furst D.E. Clinical pharmacology of combination DMARD therapy in rheumatoid arthritis. J. Rheumatol., 23, 86, 1996.
17. Miyosi T., Shinomiya F. et al. Clinical efficacy and adverse reaction of bucillamine administration for rheumatoid arthritis. Rheumatology, 12, 224, 1994.